Mahendra Deonarain,
Chief Science & Operating Officer
Dr Deonarain obtained a first class degree in Biochemistry at Imperial College in 1988, and went on to Cambridge University in 1991 where he carried out his PhD research into protein engineering. Dr Deonarain's interests in antibody therapeutics started when he was a post-doctoral research fellow at the Imperial Cancer Research Fund where he led the development of a number of antibody based therapeutic molecules that have been patented. In 1997, he was appointed as a lecturer in the Department of Biological Sciences at Imperial College and set up a research group working on the development of recombinant antibodies for therapy. In 2010 he was promoted to Reader in Antibody Technology at Imperial and his research is now focused on antibody-targeted photodynamic therapy (PDT), high affinity antibody libraries and antibody pharmacokinetic modulation. Dr Deonarain is now a biotechnology consultant working for a number of university-based spin-out enterprises developing cancer therapeutics and retains honorary links with Imperial College. He has published more than 60 papers and patents in the area of protein and
antibody engineering and conjugates. In 2001, he co-founded PhotoBiotics to commercially develop antibody-targeted PDT, which is close to entering clinical development with its lead product. He is PhotoBiotics’ Chief Science Officer.
|
|
|
